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I n Japan,  colorectal cancer (CRC) has a high mor-tality rate for both males and females,  and it is one 
of the most common malignancies: in 2011,  it showed 
4 th (14.5%) incidence rate in males and 2nd (14.9%) in 
females [1].  In a 2004-2007 study,  the distribution of 
clinical stages among CRC patients who underwent 
initial treatment showed that the proportions of stage I,  
II and III CRC cases were comparable.  However,  the 
5-year relative survival rate of stage I CRC patients was 
high at over 97% for both males and females,  and the 
10-year relative survival rate was still high at over 94%.  
Therefore,  a screening system to detect earlier stage of 
CRC is more important to decrease morbidity and mor-
tality [1].
Epidemiological studies have revealed that most 
CRCs can be ascribed to dietary,  environmental and 
lifestyle factors,  and of these factors cigarette smoking 
and alcohol consumption significantly influence the risk 
of CRC development [2-7].  A number of epidemiolog-
ical studies across the world have found that alcohol 
consumption has a more significant positive association 
with the risk of CRC in Japanese than in Western popu-
lations [8].
Acta Med.  Okayama,  2017
Vol.  71,  No.  1,  pp.  59-68
CopyrightⒸ 2017 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Original Article
Human RAD 17 Polymorphism at Codon 546 Is Associated with the  
Risk of Colorectal Cancer
Yukiko Yasudaa,  Akiko Sakaia＊,  Sachio Itoa,  Kaori Sasaia,  Hiromasa Yamamotob,   
Nagahide Matsubarac,  Mamoru Ouchidaa,  Hiroshi Katayamaa,  and Kenji Shimizua
Departments of aMolecular Oncology,  bGeneral Thoracic Surgery and Breast and Endocrinological Surgery,   
cGastroenterological Surgery,  Okayama University Graduate School of Medicine,   
Dentistry and Pharmaceutical Sciences,  Okayama 700-8558,  Japan
Human RAD17 acts as an activator of checkpoint signals in response to DNA damage.  Here we evaluated the 
association of hRAD17 Leu546Arg (rs1045051),  a missense single nucleotide polymorphism,  with the risk of 
colorectal cancer (CRC) in relation to smoking and alcohol consumption habits in 212 CRC patients and 1,142 
cancer-free controls in a case-control study conducted in Japan.  The results showed that the hRAD17 Leu/Arg 
genotype compared to the Leu/Leu genotypes was significantly associated with the protective effect on CRC risk 
with the adjusted odds ratio (OR) of 0.68 [95% confidence interval (CI): 0.49 − 0.95,  p = 0.024],  and the males 
with the Arg/Arg genotype had a greater risk of CRC compared to those with the Leu/Leu and Leu/Arg geno-
types (OR = 1.87,  95%CI 1.03 − 3.40,  p= 0.04).  In stratified studies,  the protective effect of the Leu/Arg geno-
type on CRC risk was markedly higher in the light smokers (< 20 pack years) (OR = 0.61,  95%CI 0.40 − 0.94,  
p = 0.024) and the rectal cancer patients (OR = 0.49,  95%CI 0.31 − 0.78,  p = 0.003).  The risk of the Arg/Arg gen-
otype was associated with heavy smoking (≥ 20 pack-years) (OR = 2.24,  95%CI 1.09 − 4.61,  p = 0.03).  These 
findings suggest that the genetic variant of hRAD17 Leu546Arg polymorphism has a significant effect on CRC 
susceptibility in Japanese.
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Human RAD17,  a human homologue of the yeast 
Schizosaccharomyces pombe cell-cycle checkpoint gene 
RAD17,  plays an important role in cell-cycle arrest with 
CHK1 activation and DNA damage repair in response 
to DNA damage and incomplete DNA replication by the 
phosphorylation of hRAD17 protein by ATR [9-15].  
Two significant regions in hRAD17 protein are the 
P-loop (also known as Walker A motif),  which is criti-
cal for the nucleotide binding of ATPases,  and the C 
terminus containing two SQ motifs (Ser635 and Ser645) 
that are strong targets for ATR kinase.  For the hRAD17 
function of assisting interaction with the RAD9-HUS1-
RAD1 complex,  the phosphorylation of both SQ sites is 
essential and is associated with the activation of the 
G2/M checkpoint [13-15].
hRAD17 is known to be overexpressed in CRC rela-
tive to normal colon [9].  The expression of hRAD17 in 
an S.  pombe RAD17-deleted strain induced a reduction 
of yeast colony growth and slower progression through 
the cell cycle [16].  These findings suggest that hRAD17 
is associated with the regulation of tumor growth.  In 
addition to altered expression,  genetic polymorphisms 
in genes related to DNA damage repair are known to be 
associates with the development of CRC [17].  We pre-
viously reported the association of the Arg/Arg geno-
type of hRAD17 Leu546Arg (rs1045051) polymorphism 
with the risk of esophageal squamous cell carcinoma 
[18].  As hRAD17 Leu546Arg polymorphism is located 
near the SQ motif,  we speculated that the amino acid 
substitutions from leucine to arginine at codon 546 may 
have an effect on the ATR-dependent phosphorylation 
and that the deregulation may negatively or positively 
affect tumor development.
In the present study,  we investigated the effect of 
hRAD17 Leu546Arg polymorphism on the risk of CRC 
in relation to cigarette smoking and alcohol consump-
tion habits in Japanese.
Materials and Methods
Study population. We retrospectively examined 
the cases of 212 Japanese patients with primary colorec-
tal cancer whose tumors were operated on and histolog-
ically confirmed at Okayama University Hospital 
(Okayama,  Japan) from 1994 to 2005.  The clinical and 
histopathological classifications of the tumors were 
defined according to the criteria of the UICC Tumor-
Node-Metastasis Classification of Malignant Tumors 
(TNM),  6th edition,  2002.  There were two hereditary 
CRC cases (one case of hereditary non-polyposis col-
orectal cancer and one case of familial adenomatous 
polyposis) and one case of ulcerative colitis-associated 
colorectal cancer,  and these cases were also included in 
the analysis.
The controls were 1,142 Japanese who consisted of 
two groups: 228 outpatients without cancer who visited 
the Kusaka Hospital at Okayama in 2005,  and 914 
healthy individuals who attended Junpukai Health Care 
Center at Okayama in 2009.
All patients and controls gave their written informed 
consent to have their information analyzed and pub-
lished.  The Bioethics Committee of Okayama University 
Medical School approved this study.
The age,  gender,  personal and family medical histo-
ries,  and smoking and drinking history of the subjects 
were obtained from interviews and medical question-
naire records.  The smoking status was assessed by 
pack-year equivalents ([cigarettes/day ÷ 20] × [smoking 
years]).  The classifications of smoking status for the 
present study was as follows: non-smoker,  < 20 pack-
years (light smokers),  or ≥ 20 pack-years (heavy smok-
ers).  Alcohol consumption status was assessed as the 
daily ethanol intake using the method of calculating 
alcohol consumption (one serving of sake contains 
nearly 23 g ethanol,  which is roughly the equivalent of 
two U.S. standard drinks,  when one U.S. drink’s con-
tents = 14 g of ethanol) [5].  The recommended daily 
maximum amount of alcohol was based on the report 
regarding the limitation on daily ethanol intake issued 
by the Ministry of Health,  Labor and Welfare (20 g/
day; Healthy Japan 21,  a national healthcare move-
ment).  The results of a prospective large cohort study 
showed that the risk of cancer mortality was lowest 
among Japanese drinkers with ethanol intake < 23 g/day 
[5].  The subjects were classified as non-drinkers,  < 23 g/
day (light drinkers),  or ≥ 23 g/day (heavy drinkers).
Genotype analysis. Genomic DNA was extracted 
from peripheral blood lymphocytes or freshly frozen 
non-neoplastic colorectal mucosae by the standard pro-
cedures using proteinase K and phenol-chloroform.  
The genotyping of the polymorphisms including the 
hRAD17 Leu546Arg (rs1045051) was performed by the 
SNaPshot method as described [16].  Briefly,  the target 
region for genotyping was amplified by polymerase 
chain reaction (PCR),  with a final reaction volume of 
10 µl containing 10 ng of template DNA,  1.0 pmol of 
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each primer,  2.0 mM of each dNTP,  1 µl of 10 × PCR 
buffer,  and 0.25 units of Taq DNA polymerase (TaKaRa 
Bio,  Kusatsu,  Shiga,  Japan).
Thermal cycling was performed with an initial dena-
turation at 94°C for 3 min,  followed by 32 cycles at 
94°C for 30 sec,  60°C for 30 sec and 72°C for 30 sec,  
and final extension at 72°C for 7 min.  The PCR prod-
ucts were treated with 2.0 units of exonuclease I and 
shrimp alkaline phosphatase to remove the unreacted 
primers and dNTPs by incubating at 37°C for 90 min 
and at 75°C for 15 min.  The first PCR primer set was 
designed as: sense 5’-CAGTATCGGGAAAATTGCC 
TGG-3’ and anti-sense 5’-GGACAGTAGAGACTCCC 
CCT-3’.
Next,  a single nucleotide primer extension reaction 
was performed using an ABI PRISM SNaPshot kit 
(Applied Biosystems,  Foster City,  CA,  USA) with a 
final reaction volume of 10 µl containing 3 µl of the 
purified PCR products,  20 mM of (NH4)2SO4,  and 2 µl 
of SNaPshot Ready Reaction mix containing fluores-
cently labeled ddNTPs and DNA polymerase.  The typ-
ing primer used for hRAD17 Leu546Arg was 
5’-TTTTTTTTTTTTTTTTTTTTCAAGGTATGGC 
AATAGCTGAGTTTGG-3’.  Thermal cycling was per-
formed with an initial denaturation at 96°C for 3 min,  
followed by 30 cycles at 96°C for 10 sec,  50°C for 5 sec 
and 60°C for 30 sec.
After treatment with 1.0 unit of shrimp alkaline 
phosphatase to remove the unincorporated ddNTPs by 
incubating at 37°C for 90 min and at 75°C for 15 min,  
8.5 µl of HI-Di formamide,  0.5 µl of Genescan 120 LIZ 
size standard (Applied Biosystems) and 1 µl of the reac-
tion mixture were combined and denatured at 95°C for 
5 min and placed at 4°C for 2 min.  The products were 
electrophoresed with an ABI PRISM 3100 Genetic 
Analyzer (Applied Biosystems) and analyzed by Gene 
Mapper Software SNaPshot Analysis (Applied 
Biosystems).
Statistical analysis. The allele frequency was cal-
culated by direct counting.  Deviation of the genotype 
frequency from Hardy-Weinberg equilibrium was ana-
lyzed by the exact test.  The distribution of genotype 
frequencies between the cancer cases and controls were 
analyzed using Chi-square tests.  The risk of colorectal 
cancer was estimated using odds ratio (ORs) and 95% 
confidence interval (CIs).  Analyses were adjusted for 
age,  smoking status and alcohol consumption status 
using a multivariate logistic regression model by com-
paring the genotypes between the cases and controls.  
P-values < 0.05 were considered significant.  All analyses 
were performed with SPSS software (ver. 12.0,  SPSS,  
Tokyo).
Results
The characteristics of the CRC patients and the con-
trols are summarized in Table 1.  There were significant 
differences in the age distribution and the daily alcohol 
consumption between the CRC patients and controls.  
The ratio of males to females and smoking habit did not 
show any significant difference.  Among the control 
subjects recruited from the 2 groups in Okayama,  we 
assessed the genotype distributions of hRAD17 
Leu546Arg polymorphism by Hardy-Weinberg equilib-
rium (HWE),  and the p-value was 0.55 for the Kusaka 
Hospital outpatients without cancer and 0.79 for the 
healthy individuals who attended Junpukai Health Care 
Center (data not shown).
Table 2 shows the allele and genotype frequencies of 
the hRAD17 Leu546Arg in the CRC patients and con-
trols.  The Leu/Arg genotype compared to the Leu/Leu 
genotype was significantly associated with the decreased 
risk of CRC (OR = 0.68,  95%CI 0.49 − 0.95,  p = 0.02),  
whereas the allele frequencies between the patients and 
controls were not significantly different.  Among the 
males,  the Arg/Arg genotype compared to the Leu/Leu 
and the Leu/Arg genotypes in the recessive genetic 
model was associated with a significantly increased risk 
of CRC (OR = 1.87,  95%CI 1.03 − 3.40,  p = 0.04).  We 
did not find any association between the genotypes and 
the risk of CRC among the females.
Next,  we examined the association of smoking and 
alcohol consumption history between the hRAD17 
Leu546Arg genotypes and the risk of CRC in the strati-
fied analysis (Table 3).  Among the light smokers,  the 
Leu/Arg genotype compared to the Leu/Leu genotype 
was significantly associated with a decreased risk of 
CRC (OR = 0.61,  95%CI 0.40 − 0.94,  p = 0.02).  We also 
found a significant association of the Arg/Arg genotype 
compared to the Leu/Leu and the Leu/Arg genotype in 
the recessive genetic model with an increased risk 
(OR = 2.24,  95%CI 1.09 − 4.61,  p = 0.03) among the 
heavy smokers.  There was no significant association 
among the stratified alcohol drinkers.
We further performed a stratified analysis of com-
bined smoking and alcohol consumption history on 
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Table 1　 Characteristics of the CRC patients and healthy controls
CRC patients n (%) Controls n (%) p-value
Total 212 (100.0) 1,142 (100.0)
Males 124 (58.5) 676 (59.2) 0.85
Females 88 (41.5) 466 (40.8)
Age (yrs)
　　　　<50 20 (9.4) 255 (22.3) <0.001
　　　　50-59 59 (27.8) 501 (43.9)
　　　　60-69 61 (28.8) 261 (22.9)
　　　　≥70 72 (34.0) 125 (10.9)
　　　　Median 64 55
　　　　Range 23-89 32-94
Smoking
　　　　Never 96 (46.2) 599 (52.5) 0.29
　　　<20 pack-year 31 (14.9) 182 (15.9)
　　　≥20 pack-year 81 (38.9) 361 (31.6)
Alcohol drinking＊
　　　　Never 107 (50.7) 534 (46.8) <0.001
　　　<23 g of ethanol/day 38 (18.0) 373 (32.7)
　　　≥23 g of ethanol/day 66 (31.3) 235 (20.6)
＊23 g of ethanol approximates one serving of sake,  or two U.S. standard drinks.
Table 2　 ʰʀＡＤ17 genotype in the CRC patients and controls
Genotype CRC patients n (%) Controls n (%) Adjusted OR† (95%CI) p‡
Total:
Leu/Leu 107 (50.5) 513 (44.9)
Leu/Arg 77 (36.3) 510 (44.7) 0.68 (0.49-0.95) 0.024
Arg/Arg 28 (13.2) 119 (10.4) 1.16 (0.71-1.87) 0.56
Leu/Arg+Arg/Arg 105 (49.5) 629 (55.1) 0.77 (0.56-1.04) 0.09
Leu/Leu+Leu/Arg 184 (86.8) 1,023 (89.6)
Arg/Arg 28 (13.2) 119 (10.4) 1.38 (0.87-2.18) 0.17
Allele frequencies:
Leu 291 (68.6) 1,536 (67.3) 0.58
Arg 133 (31.4) 748 (32.7)
Males:
Leu/Leu 60 (48.4) 311 (46.0)
Leu/Arg 46 (37.1) 306 (45.3) 0.71 (0.46-1.10) 0.12
Arg/Arg 18 (14.5) 59 (8.7) 1.60 (0.85-2.99) 0.14
Leu/Arg+Arg/Arg 64 (51.6) 365 (54.0) 0.85 (0.57-1.27) 0.42
Leu/Leu+Leu/Arg 106 (85.5) 617 (91.3)
Arg/Arg 18 (14.5) 59 (8.7) 1.87 (1.03-3.40) 0.039
Females:
Leu/Leu 47 (53.4) 202 (43.3)
Leu/Arg 31 (35.2) 204 (43.8) 0.65 (0.39-1.08) 0.10
Arg/Arg 10 (11.4) 60 (12.9) 0.75 (0.35-1.63) 0.47
Leu/Arg+Arg/Arg 41 (46.6) 264 (56.7) 0.67 (0.42-1.08) 0.10
Leu/Leu+Leu/Arg 78 (88.6) 406 (87.1)
Arg/Arg 10 (11.4) 60 (12.9) 0.92 (0.44-1.92) 0.83
†Adjusted for sex,  age,  smoking,  and alcohol drinking.
‡p-values,  diﬀerence in genotype frequencies between the CRC patients and controls.
hRAD17 Leu546Arg genotype in the patients and con-
trols (Table 4).  Among the group of light smokers/
heavy drinkers,  the Leu/Arg genotype compared to the 
Leu/Leu genotype was significantly associated with a 
decreased risk of CRC (OR = 0.32,  95%CI 0.11 − 0.98,  
p = 0.046).  The Arg/Arg genotype compared to the Leu/
Leu and the Leu/Arg genotypes in the recessive model 
increased the risk among the heavy smokers/light 
drinkers (OR = 2.89,  95%CI 1.11 − 7.51,  p = 0.03).  No 
significant association was revealed between the risk of 
CRC and any genotypes within the group of heavy 
smokers/heavy drinkers,  as well as the light smokers/
light drinkers.
The results of the stratified analysis of smoking and 
alcohol consumption history on hRAD17 Leu546Arg 
genotype among the males are summarized in Table 5.  
In only the group of heavy smokers,  the Arg/Arg geno-
type compared to the Leu/Leu and the Leu/Arg geno-
types in the recessive model showed a significant asso-
ciation with the risk of CRC (OR = 2.53,  95%CI 1.19 − 
5.39,  p = 0.016).  Our stratified analysis of the combined 
effect of smoking and alcohol consumption history 
among the males showed that the Arg/Arg genotype 
compared to the Leu/Leu and the Leu/Arg genotypes 
also had a significant risk among the heavy smokers/
light drinkers (OR = 3.10,  95%CI 1.13 − 8.48,  p = 0.028) 
(Table 6).
As it is known that the left and right colon have dif-
ferent embryologic origins and consequently different 
molecular backgrounds,  we analyzed the association of 
those cancer locations with the hRAD17 Leu546Arg 
genotypes.  In the separate evaluation of the left side of 
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Table 3　 Association of ʰʀＡＤ17 genotypes with smoking and alcohol consumption status
Genotype CRC patients n (%) Controls n (%) Adjusted OR＊ (95%CI) p
Smoking<20 pack-yrs
Leu/Leu 68 (54.8) 345 (44.1)
Leu/Arg 43 (34.7) 349 (44.6) 0.61 (0.40-0.94) 0.024
Arg/Arg 13 (10.5) 88 (11.3) 0.78 (0.41-1.50) 0.45
Leu/Arg+Arg/Arg 56 (45.2) 437 (55.9) 0.65 (0.44-0.96) 0.029
Leu/Leu+Leu/Arg 111 (89.5) 694 (88.7)
Arg/Arg 13 (10.5) 88 (11.3) 0.97 (0.51-1.82) 0.91
Smoking≥20 pack-yrs
Leu/Leu 38 (45.2) 168 (46.7)
Leu/Arg 31 (36.9) 161 (44.7) 0.82 (0.47-1.42) 0.47
Arg/Arg 15 (17.9) 31 (8.6) 2.04 (0.95-4.38) 0.07
Leu/Arg+Arg/Arg 46 (54.8) 192 (53.3) 1.01 (0.61-1.69) 0.96
Leu/Leu+Leu/Arg 69 (82.1) 329 (91.4)
Arg/Arg 15 (17.9) 31 (8.6) 2.24 (1.09-4.61) 0.028
Alcohol<23 g of ethanol/day
Leu/Leu 71 (49.0) 409 (45.1)
Leu/Arg 54 (37.2) 398 (43.9) 0.75 (0.50-1.11) 0.14
Arg/Arg 20 (13.8) 100 (11.0) 1.17 (0.67-2.05) 0.57
Leu/Arg+Arg/Arg 74 (51.0) 498 (54.9) 0.83 (0.58-1.19) 0.32
Leu/Leu+Leu/Arg 125 (86.2) 807 (89.0)
Arg/Arg 20 (13.8) 100 (11.0) 1.34 (0.79-2.28) 0.28
Alcohol≥23 g of ethanol/day
Leu/Leu 35 (53.0) 104 (44.3)
Leu/Arg 23 (34.8) 112 (47.7) 0.54 (0.28-1.01) 0.06
Arg/Arg 8 (12.1) 19 (8.1) 1.05 (0.39-2.83) 0.92
Leu/Arg+Arg/Arg 31 (47.0) 131 (55.7) 0.61 (0.34-1.11) 0.11
Leu/Leu+Leu/Arg 58 (87.9) 216 (91.9)
Arg/Arg 8 (12.1) 19 (8.1) 1.39 (0.54-3.62) 0.50
＊Adjusted for sex,  age,  smoking,  and alcohol drinking.
the colon (the descending colon,  sigmoid colon,  and 
rectum) and the right side of the colon (the cecum,  
ascending colon,  and transverse colon),  the Leu/Arg 
genotype compared to the Leu/Leu genotype showed a 
significant difference solely in the left colon group 
(OR = 0.64,  95%CI 0.44 − 0.93,  p = 0.02) (Table 7).  We 
further investigated the association of the genotypes 
among separate groups of colon cancer and rectal can-
cer patients.  Consistent with the results observed for 
the left and right colon,  only the rectal cancer cases 
showed a significant association for the Leu/Arg geno-
type (OR = 0.49,  95%CI 0.31 − 0.78,  p = 0.003),  whereas 
there was no significant association in colon cancer 
(Table 8).
Discussion
In this case-control study,  we examined the associa-
tion between the codon 546 polymorphism causing the 
amino acid substitution of leucine to arginine,  a mis-
sense single nucleotide polymorphism (SNP) in 
hRAD17 gene,  and the risk of CRC.  We found that the 
hRAD17 Leu546Arg variant was associated with the 
suppression or occurrence of CRC.  To our knowledge,  
this is the first report demonstrating that the hRAD17 
codon 546 polymorphism is associated with the risk of 
CRC.
In a pooled meta-analysis based on cohort and 
case-control studies across the world,  smoking was not 
shown to be associated with a significantly increased 
risk of CRC in Japanese [7],  whereas alcohol consump-
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Table 4　 Association of ʰʀＡＤ17 genotype with the combination of smoking and alcohol consumption status
Genotype CRC patients n (%) Controls n (%) Adjusted OR＊ (95%CI) p
Smoking<20 pack-yrs,  Alcohol<23 g of ethanol/day
Leu/Leu 56 (53.3) 304 (40.6)
Leu/Arg 37 (35.2) 295 (53.5) 0.69 (0.44-1.09) 0.11
Arg/Arg 12 (11.4) 82 (5.9) 0.83 (0.42-1.64) 0.59
Leu/Arg+Arg/Arg 49 (46.7) 377 (59.4) 1.39 (0.91-2.13) 0.13
Leu/Leu+Leu/Arg 93 (88.6) 599 (94.1)
Arg/Arg 12 (11.4) 82 (5.9) 0.98 (0.51-1.89) 0.94
Smoking<20 pack-yrs,  Alcohol≥23 g of ethanol/day
Leu/Leu 12 (63.2) 41 (46.5)
Leu/Arg 6 (31.6) 54 (45.6) 0.32 (0.11-0.98) 0.046
Arg/Arg 1 (5.3) 6 (8.0) 0.56 (0.06-5.44) 0.62
Leu/Arg+Arg/Arg 7 (36.8) 60 (53.5) 0.34 (0.12-1.00) 0.049
Leu/Leu+Leu/Arg 18 (94.7) 95 (92.0)
Arg/Arg 1 (5.3) 6 (8.0) 0.96 (0.10-8.90) 0.97
Smoking≥20 pack-yrs,  Alcohol<23 g of ethanol/day
Leu/Leu 15 (39.5) 105 (47.0)
Leu/Arg 15 (39.5) 103 (43.3) 0.93 (0.42-2.06) 0.86
Arg/Arg 8 (21.1) 18 (9.7) 2.79 (0.99-7.84) 0.05
Leu/Arg+Arg/Arg 23 (60.5) 121 (53.0) 1.22 (0.59-2.51) 0.60
Leu/Leu+Leu/Arg 30 (78.9) 208 (90.3)
Arg/Arg 8 (21.1) 18 (9.7) 2.89 (1.11-7.51) 0.030
Smoking≥20 pack-yrs,  Alcohol≥23 g of ethanol/day
Leu/Leu 23 (50.0) 63 (47.0)
Leu/Arg 16 (34.8) 58 (43.3) 0.75 (0.34-1.66) 0.48
Arg/Arg 7 (15.2) 13 (9.7) 1.74 (0.53-5.76) 0.36
Leu/Arg+Arg/Arg 23 (50.0) 71 (53.0) 0.90 (0.43-1.87) 0.77
Leu/Leu+Leu/Arg 39 (84.8) 121 (90.3)
Arg/Arg 7 (15.2) 13 (9.7) 1.99 (0.63-6.24) 0.24
＊Adjusted for sex,  age,  smoking,  and alcohol drinking.
tion showed a significant positive association with the 
risk of CRC in Western populations [8].  In the present 
study,  the consumption of more than 23 g of ethanol/
day was significantly associated with the risk of CRC,  
but smoking status had no association with the risk of 
CRC.  Since several studies have revealed that long-term 
heavy smoking is associated with a higher risk of CRC,  
it is speculated that smoking plays an important role in 
the initiation of CRC.  and it is thought that the car-
cinogenic effects of smoking on CRC development 
require a long induction period.  The proportion of 
long-term smokers probably affects the association 
between smoking and the risk of CRC [7 , 19].
Comparing males and females,  the patients and 
controls showed different lifestyle tendencies.  The 
number of male CRC patients who were heavy smok-
ers/heavy alcohol drinkers was the largest in the com-
bined stratified analysis of smoking and alcohol con-
sumption history,  whereas the light smokers/light 
alcohol drinkers were the most numerous among the 
females in both the patient and control groups.
We reported that the Arg/Arg genotype of hRAD17 
Leu546Arg polymorphism compared to the Leu/Leu 
genotype and the Leu/Arg genotype in a recessive 
model was significantly associated with an increased 
risk of esophageal squamous carcinoma in the study’s 
group of male light alcohol drinkers [18].  In the strati-
fied analysis of CRC patients in the present study,  alco-
hol consumption in the males did not show any associ-
ation with the risk of hRAD17 polymorphism.  In the 
combined stratified analysis of smoking and alcohol 
consumption,  we did not observe an association of 
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Table 5　 Association of ʰʀＡＤ17 genotypes with smoking and alcohol consumption status in the males
Genotype CRC patients n (%) Controls n (%) Adjusted OR＊ (95%CI) p
Smoking<20 pack-yrs
Leu/Leu 23 (56.1) 149 (44.3)
Leu/Arg 14 (34.1) 156 (46.4) 0.56 (0.28-1.14) 0.11
Arg/Arg 4 (9.8) 31 (9.2) 0.84 (0.27-2.61) 0.76
Leu/Arg+Arg/Arg 18 (43.9) 187 (55.7) 0.61 (0.31-1.17) 0.14
Leu/Leu+Leu/Arg 37 (90.2) 305 (90.8)
Arg/Arg 4 (9.8) 31 (9.2) 1.08 (0.36-3.25) 0.89
Smoking≥20 pack-yrs
Leu/Leu 36 (45.6) 162 (47.6)
Leu/Arg 29 (36.7) 150 (44.1) 0.83 (0.47-1.47) 0.53
Arg/Arg 14 (17.7) 28 (8.2) 2.32 (1.04-5.16) 0.039
Leu/Arg+Arg/Arg 43 (54.4) 178 (52.4) 1.05 (0.62-1.78) 0.84
Leu/Leu+Leu/Arg 65 (82.3) 312 (91.8)
Arg/Arg 14 (17.7) 28 (8.2) 2.53 (1.19-5.39) 0.016
Alcohol<23 g of ethanol/day
Leu/Leu 27 (43.5) 213 (46.6)
Leu/Arg 25 (40.3) 202 (44.2) 0.88 (0.48-1.61) 0.68
Arg/Arg 10 (16.1) 42 (9.2) 1.87 (0.83-4.20) 0.13
Leu/Arg+Arg/Arg 35 (56.5) 244 (53.4) 1.05 (0.61-1.82) 0.85
Leu/Leu+Leu/Arg 52 (83.9) 415 (90.8)
Arg/Arg 10 (16.1) 42 (9.2) 1.98 (0.92-4.24) 0.08
Alcohol≥23 g of ethanol/day
Leu/Leu 32 (52.5) 98 (44.7)
Leu/Arg 21 (34.4) 104 (47.5) 0.55 (0.29-1.07) 0.08
Arg/Arg 8 (13.1) 17 (7.8) 1.27 (0.46-3.48) 0.65
Leu/Arg+Arg/Arg 29 (47.5) 121 (55.3) 0.65 (0.35-1.21) 0.18
Leu/Leu+Leu/Arg 53 (86.9) 202 (92.2)
Arg/Arg 8 (13.1) 17 (7.8) 1.66 (0.63-4.37) 0.31
＊Adjusted for age,  smoking,  and alcohol drinking.
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Table 7　 Association of ʰʀＡＤ17 genotype with right and left colon cancer
Genotype CRC patients n (%) Controls n (%) Adjusted OR＊ (95%CI) p
Right colon cancer:
Leu/Leu 22 (44.9) 513 (44.9)
Leu/Arg 20 (40.8) 510 (44.7) 0.75 (0.41-1.38) 0.36
Arg/Arg 7 (14.3) 119 (10.4) 1.37 (0.59-3.17) 0.46
Leu/Arg+Arg/Arg 27 (55.1) 629 (55.1) 0.87 (0.50-1.51) 0.61
Leu/Leu+Leu/Arg 42 (85.7) 1,023 (89.6)
Arg/Arg 7 (14.3) 119 (10.4) 1.57 (0.71-3.46) 0.22
Left colon cancer:
Leu/Leu 81 (51.9) 513 (44.9)
Leu/Arg 55 (35.3) 510 (44.7) 0.64 (0.44-0.93) 0.02
Arg/Arg 20 (12.8) 119 (10.4) 1.07 (0.63-1.84) 0.80
Leu/Arg+Arg/Arg 75 (48.1) 629 (55.1) 0.72 (0.51-1.02) 0.06
Leu/Leu+Leu/Arg 136 (87.2) 1,023 (89.6)
Arg/Arg 20 (12.8) 119 (10.4) 1.31 (0.78-2.19) 0.31
＊Adjusted for sex,  age,  smoking,  and alcohol drinking.
Table 6　 Association of ʰʀＡＤ17 genotype with combination of smoking and alcohol consumption status in males
Genotype CRC patients n (%) Controls n (%) Adjusted OR＊ (95%CI) p
Smoking<20 pack-yrs Alcohol<23 g of ethanol/day
Leu/Leu 14 (51.9) 114 (46.0)
Leu/Arg 10 (37.0) 109 (44.0) 0.76 (0.32-1.80) 0.54
Arg/Arg 3 (11.1) 25 (10.1) 0.98 (0.26-3.68) 0.98
Leu/Arg+Arg/Arg 13 (48.1) 134 (54.0) 0.80 (0.36-1.79) 0.59
Leu/Leu+Leu/Arg 24 (88.9) 223 (89.9)
Arg/Arg 3 (11.1) 25 (10.1) 1.11 (0.31-3.95) 0.87
Smoking<20 pack-yrs Alcohol≥23 g of ethanol/day
Leu/Leu 9 (64.3) 35 (39.8)
Leu/Arg 4 (28.6) 47 (53.4) 0.29 (0.08-1.06) 0.06
Arg/Arg 1 (7.1) 6 (6.8) 0.57 (0.06-5.50) 0.63
Leu/Arg+Arg/Arg 5 (35.7) 53 (60.2) 0.33 (0.10-1.08) 0.07
Leu/Leu+Leu/Arg 13 (92.9) 82 (93.2)
Arg/Arg 1 (7.1) 6 (6.8) 1.01 (0.11-9.12) 0.99
Smoking≥20 pack-yrs Alcohol<23 g of ethanol/day
Leu/Leu 13 (39.4) 99 (47.4)
Leu/Arg 13 (39.4) 93 (44.5) 0.97 (0.42-2.27) 0.95
Arg/Arg 7 (21.2) 17 (8.1) 3.05 (1.03-9.07) 0.045
Leu/Arg+Arg/Arg 20 (60.6) 110 (52.6) 1.29 (0.60-2.81) 0.51
Leu/Leu+Leu/Arg 26 (78.8) 192 (91.9)
Arg/Arg 7 (21.2) 17 (8.1) 3.10 (1.13-8.48) 0.028
Smoking≥20 pack-yrs Alcohol≥23 g of ethanol/day
Leu/Leu 23 (50.0) 63 (48.1)
Leu/Arg 16 (34.8) 57 (43.5) 0.75 (0.34-1.66) 0.48
Arg/Arg 7 (15.2) 11 (8.4) 1.74 (0.53-5.76) 0.36
Leu/Arg+Arg/Arg 23 (50.0) 68 (51.9) 0.90 (0.43-1.87) 0.77
Leu/Leu+Leu/Arg 39 (84.8) 120 (91.6)
Arg/Arg 7 (15.2) 11 (8.4) 1.99 (0.63-6.24) 0.24
＊Adjusted for age,  smoking,  and alcohol drinking.
increased CRC risk between hRAD17 polymorphism 
and heavy smokers/heavy drinkers.  However,  the Arg/
Arg genotype compared to the Leu/Leu genotype and 
the Leu/Arg genotype in the recessive model was asso-
ciated with an increased risk of CRC among the heavy 
smokers/light drinkers.  Our results demonstrated that 
in males,  cigarette smoking rather than alcohol con-
sumption has a strong association between hRAD17 
polymorphism and the risk of CRC,  unlike the findings 
for esophageal squamous cell carcinoma.  The larger 
proportion of our present patients who were heavy 
smokers compared to the controls is probably attribut-
able to the cumulative effect of DNA damage induced by 
chronic cigarette smoke.
A pooled meta-analysis of cohort studies revealed 
that in females,  alcohol intakes more than 23 g etha-
nol/day was also reported to be associated with a higher 
risk of CRC by [8].  However,  in the present females-
only stratified analysis of lifestyle habits,  no significant 
association of increased or decreased risk of CRC with 
either ethanol intake or hRAD17 polymorphism was 
observed (data not shown).
Concerning the location of the cancer,  the left colon 
and the right colon are developed from different 
embryonic origins,  and they show different physiology 
and molecular backgrounds [20 , 21].  Generally,  the 
right (proximal) colon cancer responds more poorly to 
chemotherapy compared to the left (distal) colon.  In 
our patient series,  only the left (distal) colon cancer and 
rectal cancer cases showed a significant association with 
the hRAD17 Leu/Arg genotype.  The implications of this 
difference remain to be elucidated.
It was reported that the association of smoking with 
rectal cancer among Japanese is stronger than that with 
colon cancer [7].  Although the association of smoking 
with the hRAD17 genotype in rectal cancer was exam-
ined in the present study,  a significant finding was not 
observed.
There were several limitations including small sam-
ple size,  some self-selection bias for control group and 
inadequate adjustment for various confounding factors 
in our case-control study.  For the subsequent stratified 
analyses,  the small sample size might limit the statisti-
cal power of our study.  We could not analyze a more 
detailed stratification of the present cases with the com-
bined association of sex,  lifestyle habit and the primary 
area of colorectal cancer because of the small number of 
female heavy smokers and heavy drinkers.  Nonetheless,  
we identified the association between hRAD17 poly-
morphism and the increased- and decreased-risk groups 
of CRC patients.
In conclusion,  we found that in a Japanese popula-
tion,  the variant allele of hRAD17 is significantly asso-
ciated with a decreased risk of CRC among light smok-
ers and rectal cancer patients and with an increased risk 
of CRC among heavy smokers.  Larger studies on the 
hRAD17 polymorphisms are warranted to test our 
results,  and the genotyping of hRAD17 codon546 could 
eventually enable the identification of individuals at 
high risk for the development of CRC cohort,  giving 
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Table 8　 Association of ʰʀＡＤ17 genotype with colon cancer and rectal cancer
Genotype CRC patients n (%) Controls n (%) Adjusted OR＊ (95%CI) p
Colon Cancer:
Leu/Leu 45 (43.7) 513 (44.9)
Leu/Arg 44 (42.7) 510 (44.7) 0.91 (0.58-1.43) 0.69
Arg/Arg 14 (13.6) 119 (10.4) 1.41 (0.73-2.71) 0.30
Leu/Arg+Arg/Arg 58 (56.3) 629 (55.1) 1.00 (0.66-1.53) 0.99
Leu/Leu+Leu/Arg 89 (86.4) 1,023 (89.6)
Arg/Arg 14 (13.6) 119 (10.4) 1.47 (0.80-2.73) 0.22
Rectal Cancer:
Leu/Leu 60 (57.1) 513 (44.9)
Leu/Arg 31 (29.5) 510 (44.7) 0.49 (0.31-0.78) 0.003
Arg/Arg 14 (13.3) 119 (10.4) 0.98 (0.52-1.86) 0.95
Leu/Arg+Arg/Arg 45 (42.9) 629 (55.1) 0.58 (0.38-0.89) 0.012
Leu/Leu+Leu/Arg 91 (86.7) 1,023 (89.6)
Arg/Arg 14 (13.3) 119 (10.4) 1.32 (0.71-2.45) 0.38
＊Adjusted for sex,  age,  smoking,  and alcohol drinking.
these individuals the incentive to improve their lifestyle 
habits.
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